2f54 › Citations

Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity.

Dunn SM, Rizkallah PJ, Baston E, Mahon T, Cameron B, Moysey R, Gao F, Sami M, Boulter J, Li Y, Jakobsen BK
Protein Sci 15 710-21 (2006)
Cited: 73 times
EuropePMC logo PMID: 16600963

Abstract

The mammalian alpha/beta T cell receptor (TCR) repertoire plays a pivotal role in adaptive immunity by recognizing short, processed, peptide antigens bound in the context of a highly diverse family of cell-surface major histocompatibility complexes (pMHCs). Despite the extensive TCR-MHC interaction surface, peptide-independent cross-reactivity of native TCRs is generally avoided through cell-mediated selection of molecules with low inherent affinity for MHC. Here we show that, contrary to expectations, the germ line-encoded complementarity determining regions (CDRs) of human TCRs, namely the CDR2s, which appear to contact only the MHC surface and not the bound peptide, can be engineered to yield soluble low nanomolar affinity ligands that retain a surprisingly high degree of specificity for the cognate pMHC target. Structural investigation of one such CDR2 mutant implicates shape complementarity of the mutant CDR2 contact interfaces as being a key determinant of the increased affinity. Our results suggest that manipulation of germ line CDR2 loops may provide a useful route to the production of high-affinity TCRs with therapeutic and diagnostic potential.

Articles - 2f54 mentioned but not cited (8)

  1. Directed evolution of human T cell receptor CDR2 residues by phage display dramatically enhances affinity for cognate peptide-MHC without increasing apparent cross-reactivity. Dunn SM, Rizkallah PJ, Baston E, Mahon T, Cameron B, Moysey R, Gao F, Sami M, Boulter J, Li Y, Jakobsen BK. Protein Sci 15 710-721 (2006)
  2. Mechano-regulation of Peptide-MHC Class I Conformations Determines TCR Antigen Recognition. Wu P, Zhang T, Liu B, Fei P, Cui L, Qin R, Zhu H, Yao D, Martinez RJ, Hu W, An C, Zhang Y, Liu J, Shi J, Fan J, Yin W, Sun J, Zhou C, Zeng X, Xu C, Wang J, Evavold BD, Zhu C, Chen W, Lou J. Mol Cell 73 1015-1027.e7 (2019)
  3. Predicting peptide binding affinities to MHC molecules using a modified semi-empirical scoring function. Liao WW, Arthur JW. PLoS One 6 e25055 (2011)
  4. Differential geometric analysis of alterations in MH α-helices. Hischenhuber B, Havlicek H, Todoric J, Höllrigl-Binder S, Schreiner W, Knapp B. J Comput Chem 34 1862-1879 (2013)
  5. DynaDom: structure-based prediction of T cell receptor inter-domain and T cell receptor-peptide-MHC (class I) association angles. Hoffmann T, Marion A, Antes I. BMC Struct Biol 17 2 (2017)
  6. Quantitative Analysis of the Association Angle between T-cell Receptor Vα/Vβ Domains Reveals Important Features for Epitope Recognition. Hoffmann T, Krackhardt AM, Antes I. PLoS Comput Biol 11 e1004244 (2015)
  7. Understanding TR binding to pMHC complexes: how does a TR scan many pMHC complexes yet preferentially bind to one. Khan JM, Ranganathan S. PLoS One 6 e17194 (2011)
  8. Stabilization of soluble high-affinity T-cell receptor with de novo disulfide bonds. Sádio F, Stadlmayr G, Stadlbauer K, Gräf M, Scharrer A, Rüker F, Wozniak-Knopp G. FEBS Lett 594 477-490 (2020)


Reviews citing this publication (17)

  1. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. Chandran SS, Klebanoff CA. Immunol Rev 290 127-147 (2019)
  2. MM-GBSA binding free energy decomposition and T cell receptor engineering. Zoete V, Irving MB, Michielin O. J Mol Recognit 23 142-152 (2010)
  3. ImmTACs for targeted cancer therapy: Why, what, how, and which. Oates J, Hassan NJ, Jakobsen BK. Mol Immunol 67 67-74 (2015)
  4. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Damato BE, Dukes J, Goodall H, Carvajal RD. Cancers (Basel) 11 E971 (2019)
  5. Genetic engineering of T cells for adoptive immunotherapy. Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, Scholler J, Hao X, Mexas A, Carroll RG, June CH, Riley JL. Immunol Res 42 166-181 (2008)
  6. Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Hebeisen M, Allard M, Gannon PO, Schmidt J, Speiser DE, Rufer N. Front Immunol 6 582 (2015)
  7. Display, engineering, and applications of antigen-specific T cell receptors. Richman SA, Kranz DM. Biomol Eng 24 361-373 (2007)
  8. Structure-Based, Rational Design of T Cell Receptors. Zoete V, Irving M, Ferber M, Cuendet MA, Michielin O. Front Immunol 4 268 (2013)
  9. Challenges in T cell receptor gene therapy. Uttenthal BJ, Chua I, Morris EC, Stauss HJ. J Gene Med 14 386-399 (2012)
  10. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy. Rath JA, Arber C. Cells 9 E1485 (2020)
  11. Diversity-oriented approaches for interrogating T-cell receptor repertoire, ligand recognition, and function. Birnbaum ME, Dong S, Garcia KC. Immunol Rev 250 82-101 (2012)
  12. Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. Jones HF, Molvi Z, Klatt MG, Dao T, Scheinberg DA. Front Immunol 11 585385 (2020)
  13. Integrating Experiment and Theory to Understand TCR-pMHC Dynamics. Buckle AM, Borg NA. Front Immunol 9 2898 (2018)
  14. Enhanced T cell receptor gene therapy for cancer. Kieback E, Uckert W. Expert Opin Biol Ther 10 749-762 (2010)
  15. The intersection of affinity and specificity in the development and optimization of T cell receptor based therapeutics. Riley TP, Baker BM. Semin Cell Dev Biol 84 30-41 (2018)
  16. Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions. Løset GÅ, Berntzen G, Frigstad T, Pollmann S, Gunnarsen KS, Sandlie I. Front Oncol 4 378 (2014)
  17. Engineering the T cell receptor for fun and profit: Uncovering complex biology, interrogating the immune system, and targeting disease. Rosenberg AM, Baker BM. Curr Opin Struct Biol 74 102358 (2022)

Articles citing this publication (48)

  1. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA. J Immunol 180 6116-6131 (2008)
  2. Monoclonal TCR-redirected tumor cell killing. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK. Nat Med 18 980-987 (2012)
  3. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. Irving M, Zoete V, Hebeisen M, Schmid D, Baumgartner P, Guillaume P, Romero P, Speiser D, Luescher I, Rufer N, Michielin O. J Biol Chem 287 23068-23078 (2012)
  4. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. Hebeisen M, Baitsch L, Presotto D, Baumgaertner P, Romero P, Michielin O, Speiser DE, Rufer N. J Clin Invest 123 1044-1056 (2013)
  5. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Raman MC, Rizkallah PJ, Simmons R, Donnellan Z, Dukes J, Bossi G, Le Provost GS, Todorov P, Baston E, Hickman E, Mahon T, Hassan N, Vuidepot A, Sami M, Cole DK, Jakobsen BK. Sci Rep 6 18851 (2016)
  6. Computational design of the affinity and specificity of a therapeutic T cell receptor. Pierce BG, Hellman LM, Hossain M, Singh NK, Vander Kooi CW, Weng Z, Baker BM. PLoS Comput Biol 10 e1003478 (2014)
  7. Survey of the year 2006 commercial optical biosensor literature. Rich RL, Myszka DG. J Mol Recognit 20 300-366 (2007)
  8. Degenerate T-cell recognition of peptides on MHC molecules creates large holes in the T-cell repertoire. Calis JJ, de Boer RJ, Keşmir C. PLoS Comput Biol 8 e1002412 (2012)
  9. Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Stone JD, Kranz DM. Front Immunol 4 244 (2013)
  10. Structure-based design of a T-cell receptor leads to nearly 100-fold improvement in binding affinity for pepMHC. Haidar JN, Pierce B, Yu Y, Tong W, Li M, Weng Z. Proteins 74 948-960 (2009)
  11. Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Sami M, Rizkallah PJ, Dunn S, Molloy P, Moysey R, Vuidepot A, Baston E, Todorov P, Li Y, Gao F, Boulter JM, Jakobsen BK. Protein Eng Des Sel 20 397-403 (2007)
  12. T-cell receptor gene therapy of established tumors in a murine melanoma model. Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. J Immunother 31 1-6 (2008)
  13. T-cell receptor (TCR)-peptide specificity overrides affinity-enhancing TCR-major histocompatibility complex interactions. Cole DK, Miles KM, Madura F, Holland CJ, Schauenburg AJ, Godkin AJ, Bulek AM, Fuller A, Akpovwa HJ, Pymm PG, Liddy N, Sami M, Li Y, Rizkallah PJ, Jakobsen BK, Sewell AK. J Biol Chem 289 628-638 (2014)
  14. T cell receptor engagement of peptide-major histocompatibility complex class I does not modify CD8 binding. Cole DK, Dunn SM, Sami M, Boulter JM, Jakobsen BK, Sewell AK. Mol Immunol 45 2700-2709 (2008)
  15. Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Richman SA, Aggen DH, Dossett ML, Donermeyer DL, Allen PM, Greenberg PD, Kranz DM. Mol Immunol 46 902-916 (2009)
  16. T-cell receptor specificity maintained by altered thermodynamics. Madura F, Rizkallah PJ, Miles KM, Holland CJ, Bulek AM, Fuller A, Schauenburg AJ, Miles JJ, Liddy N, Sami M, Li Y, Hossain M, Baker BM, Jakobsen BK, Sewell AK, Cole DK. J Biol Chem 288 18766-18775 (2013)
  17. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA. Holland CJ, Crean RM, Pentier JM, de Wet B, Lloyd A, Srikannathasan V, Lissin N, Lloyd KA, Blicher TH, Conroy PJ, Hock M, Pengelly RJ, Spinner TE, Cameron B, Potter EA, Jeyanthan A, Molloy PE, Sami M, Aleksic M, Liddy N, Robinson RA, Harper S, Lepore M, Pudney CR, van der Kamp MW, Rizkallah PJ, Jakobsen BK, Vuidepot A, Cole DK. J Clin Invest 130 2673-2688 (2020)
  18. Specific increase in potency via structure-based design of a TCR. Malecek K, Grigoryan A, Zhong S, Gu WJ, Johnson LA, Rosenberg SA, Cardozo T, Krogsgaard M. J Immunol 193 2587-2599 (2014)
  19. Fine-Tuning of Optimal TCR Signaling in Tumor-Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms. Presotto D, Erdes E, Duong MN, Allard M, Regamey PO, Quadroni M, Doucey MA, Rufer N, Hebeisen M. Front Immunol 8 1564 (2017)
  20. Specific roles of each TCR hemichain in generating functional chain-centric TCR. Nakatsugawa M, Yamashita Y, Ochi T, Tanaka S, Chamoto K, Guo T, Butler MO, Hirano N. J Immunol 194 3487-3500 (2015)
  21. Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function. Thomas S, Mohammed F, Reijmers RM, Woolston A, Stauss T, Kennedy A, Stirling D, Holler A, Green L, Jones D, Matthews KK, Price DA, Chain BM, Heemskerk MHM, Morris EC, Willcox BE, Stauss HJ. Nat Commun 10 4451 (2019)
  22. Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors. Aggen DH, Chervin AS, Insaidoo FK, Piepenbrink KH, Baker BM, Kranz DM. Protein Eng Des Sel 24 361-372 (2011)
  23. Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptors. Jones LL, Colf LA, Bankovich AJ, Stone JD, Gao YG, Chan CM, Huang RH, Garcia KC, Kranz DM. Biochemistry 47 12398-12408 (2008)
  24. Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode. Cole DK, Sami M, Scott DR, Rizkallah PJ, Borbulevych OY, Todorov PT, Moysey RK, Jakobsen BK, Boulter JM, Baker BM, Yi Li. Front Immunol 4 168 (2013)
  25. Molecular insights for optimizing T cell receptor specificity against cancer. Hebeisen M, Oberle SG, Presotto D, Speiser DE, Zehn D, Rufer N. Front Immunol 4 154 (2013)
  26. Engineering improved T cell receptors using an alanine-scan guided T cell display selection system. Malecek K, Zhong S, McGary K, Yu C, Huang K, Johnson LA, Rosenberg SA, Krogsgaard M. J Immunol Methods 392 1-11 (2013)
  27. Soluble T-cell receptors produced in human cells for targeted delivery. Walseng E, Wälchli S, Fallang LE, Yang W, Vefferstad A, Areffard A, Olweus J. PLoS One 10 e0119559 (2015)
  28. Changing the peptide specificity of a human T-cell receptor by directed evolution. Smith SN, Wang Y, Baylon JL, Singh NK, Baker BM, Tajkhorshid E, Kranz DM. Nat Commun 5 5223 (2014)
  29. Directed evolution of a fluorogen-activating single chain antibody for function and enhanced brightness in the cytoplasm. Yates BP, Peck MA, Berget PB. Mol Biotechnol 54 829-841 (2013)
  30. Plasticity in the contribution of T cell receptor variable region residues to binding of peptide-HLA-A2 complexes. Smith SN, Sommermeyer D, Piepenbrink KH, Blevins SJ, Bernhard H, Uckert W, Baker BM, Kranz DM. J Mol Biol 425 4496-4507 (2013)
  31. Functional phage display of two murine alpha/beta T-cell receptors is strongly dependent on fusion format, mode and periplasmic folding assistance. Løset GÅ, Lunde E, Bogen B, Brekke OH, Sandlie I. Protein Eng Des Sel 20 461-472 (2007)
  32. T Cell Receptor Engineering and Analysis Using the Yeast Display Platform. Smith SN, Harris DT, Kranz DM. Methods Mol Biol 1319 95-141 (2015)
  33. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes. Duong MN, Erdes E, Hebeisen M, Rufer N. J Immunother Cancer 7 284 (2019)
  34. The complex and specific pMHC interactions with diverse HIV-1 TCR clonotypes reveal a structural basis for alterations in CTL function. Xia Z, Chen H, Kang SG, Huynh T, Fang JW, Lamothe PA, Walker BD, Zhou R. Sci Rep 4 4087 (2014)
  35. Can oligomeric T-cell receptor be used as a tool to detect viral peptide epitopes on infected cells? Anikeeva N, Mareeva T, Liu W, Sykulev Y. Clin Immunol 130 98-109 (2009)
  36. Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics. Froning K, Maguire J, Sereno A, Huang F, Chang S, Weichert K, Frommelt AJ, Dong J, Wu X, Austin H, Conner EM, Fitchett JR, Heng AR, Balasubramaniam D, Hilgers MT, Kuhlman B, Demarest SJ. Nat Commun 11 2330 (2020)
  37. Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells. Spear TT, Wang Y, Foley KC, Murray DC, Scurti GM, Simms PE, Garrett-Mayer E, Hellman LM, Baker BM, Nishimura MI. Cancer Immunol Immunother 66 1411-1424 (2017)
  38. Immune parameters to consider when choosing T-cell receptors for therapy. Burrows SR, Miles JJ. Front Immunol 4 229 (2013)
  39. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4. Coles CH, McMurran C, Lloyd A, Hock M, Hibbert L, Raman MCC, Hayes C, Lupardus P, Cole DK, Harper S. J Biol Chem 295 11486-11494 (2020)
  40. Tuning antiviral CD8 T-cell response via proline-altered peptide ligand vaccination. Duru AD, Sun R, Allerbring EB, Chadderton J, Kadri N, Han X, Peqini K, Uchtenhagen H, Madhurantakam C, Pellegrino S, Sandalova T, Nygren PÅ, Turner SJ, Achour A. PLoS Pathog 16 e1008244 (2020)
  41. Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy. Crean RM, MacLachlan BJ, Madura F, Whalley T, Rizkallah PJ, Holland CJ, McMurran C, Harper S, Godkin A, Sewell AK, Pudney CR, van der Kamp MW, Cole DK. Mol Ther Oncolytics 18 443-456 (2020)
  42. Rapid screening of TCR-pMHC interactions by the YAMTAD system. Wang L, Lan X. Cell Discov 8 30 (2022)
  43. Reliable In Silico Ranking of Engineered Therapeutic TCR Binding Affinities with MMPB/GBSA. Crean RM, Pudney CR, Cole DK, van der Kamp MW. J Chem Inf Model 62 577-590 (2022)
  44. Combination strategies to durably suppress HIV-1: Soluble T cell receptors. Wallace Z, Singh PK, Dorrell L. J Virus Erad 8 100082 (2022)
  45. High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation. Moysey RK, Li Y, Paston SJ, Baston EE, Sami MS, Cameron BJ, Gavarret J, Todorov P, Vuidepot A, Dunn SM, Pumphrey NJ, Adams KJ, Yuan F, Dennis RE, Sutton DH, Johnson AD, Brewer JE, Ashfield R, Lissin NM, Jakobsen BK. Protein Cell 1 1118-1127 (2010)
  46. Structure-activity relationship of T-cell receptors based on alanine scanning. Narimatsu S, Yoshioka Y, Morishige T, Yao X, Tsunoda S, Tsutsumi Y, Nishimura MI, Mukai Y, Okada N, Nakagawa S. Biochem Biophys Res Commun 415 558-562 (2011)
  47. Human T-cell receptor V gene segment of alpha and beta families: A revised primer design strategy. Ch'ng ACW, Chan SK, Ignatius J, Lim TS. Eur J Immunol 49 1186-1199 (2019)
  48. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. Poole A, Karuppiah V, Hartt A, Haidar JN, Moureau S, Dobrzycki T, Hayes C, Rowley C, Dias J, Harper S, Barnbrook K, Hock M, Coles C, Yang W, Aleksic M, Lin AB, Robinson R, Dukes JD, Liddy N, Van der Kamp M, Plowman GD, Vuidepot A, Cole DK, Whale AD, Chillakuri C. Nat Commun 13 5333 (2022)


Quick links